When Australians collect a prescription from their local pharmacy, the medicine has often travelled a remarkable journey spanning more than a decade.

Before a new treatment reaches patients, it may have progressed through years of scientific research, laboratory testing, clinical trials, regulatory assessment and commercial negotiation. Only after passing each stage does it become available through Australia's healthcare system.

The process is designed to ensure medicines are safe, effective and represent good value for both patients and taxpayers.

It Starts With an Idea

Every new medicine begins with scientific research.

Universities, biotechnology companies and pharmaceutical manufacturers study diseases, genetics and human biology to identify new ways of treating illness.

Researchers may investigate thousands of chemical compounds before finding one with genuine therapeutic potential.

Most potential medicines never progress beyond the laboratory.

Laboratory Research

Once a promising compound is identified, scientists conduct extensive laboratory testing.

Researchers seek to answer fundamental questions.

Does the medicine work?

Is it stable?

Does it appear safe?

Can it be manufactured consistently?

Only a small percentage of discoveries move to the next stage.

Clinical Trials

Before a medicine can be approved for public use, it undergoes clinical trials involving human volunteers.

These trials generally occur in several phases.

Early studies examine safety and appropriate dosage.

Larger studies compare the medicine with existing treatments or placebos to determine whether it provides genuine clinical benefit.

Clinical trials are conducted under strict ethical standards designed to protect participants while generating reliable scientific evidence.

Assessment by the Therapeutic Goods Administration

In Australia, new medicines must be assessed by the Therapeutic Goods Administration (TGA).

The TGA evaluates evidence relating to quality, safety and effectiveness before deciding whether a medicine should be registered for use in Australia.

Approval by the TGA means the medicine can legally be supplied in Australia, but it does not automatically mean it will be affordable for patients.

The PBS Assessment

Many newly approved medicines are then considered for inclusion on the Pharmaceutical Benefits Scheme (PBS).

An independent committee, the Pharmaceutical Benefits Advisory Committee (PBAC), assesses whether the medicine offers meaningful clinical benefits compared with existing treatments and whether it represents value for public funding.

This assessment considers both medical outcomes and economic evidence.

A medicine that offers only limited additional benefit at a substantially higher cost may not initially receive PBS support.

Commercial Negotiations

If a medicine is recommended for PBS listing, negotiations begin between the Australian Government and the pharmaceutical manufacturer.

The objective is to agree on a price that provides reasonable value for taxpayers while allowing companies to recover the substantial investment required to research and develop new medicines.

These negotiations are an important part of Australia's approach to maintaining affordable healthcare.

Manufacturing and Distribution

Once approved and listed, production begins at commercial scale.

Some medicines are manufactured in Australia, while many are imported from overseas production facilities operating under strict quality standards.

Medicines are distributed through national wholesalers before reaching community pharmacies, hospital pharmacies and healthcare providers across the country.

Australia's logistics network ensures medicines reach both major cities and remote communities.

Dispensing to Patients

Doctors, nurse practitioners and other authorised prescribers determine whether a medicine is appropriate for an individual patient.

Pharmacists then dispense the medicine, provide advice on its correct use, explain possible side effects and check for interactions with other medicines.

For many patients, the pharmacist becomes an ongoing partner in managing long-term health conditions.

Monitoring Continues

Approval is not the end of the process.

Medicines continue to be monitored after they enter widespread use.

Healthcare professionals, manufacturers and regulators report and investigate adverse events, allowing safety information to be updated if new evidence emerges.

This ongoing surveillance helps ensure medicines continue to meet Australia's high standards throughout their lifecycle.

Innovation Never Stops

Medical science continues to evolve.

Researchers are developing targeted cancer therapies, gene therapies, personalised medicines and treatments for previously untreatable conditions.

Each innovation begins the same journey—from laboratory research through scientific evaluation, regulatory assessment and careful implementation within Australia's healthcare system.

It is a process built on evidence, transparency and continual improvement.

The Times Health View

The medicine in a patient's hand represents far more than a successful scientific discovery. It reflects years of research, rigorous testing, careful regulation and collaboration between researchers, clinicians, manufacturers, governments and pharmacists. Every stage is designed with a single purpose: to ensure Australians receive medicines that are safe, effective and accessible. Understanding that journey helps explain why confidence in Australia's healthcare system is built not on speed alone, but on scientific evidence and public trust.